Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/11/14 19:41:55」(JST)

wiki en

Fesoterodine (INN, used as the fumarate under the brand name Toviaz) is an antimuscarinic drug developed by Schwarz Pharma AG to treat overactive bladder syndrome (OAB).^[1] It was approved by the European Medicines Agency in April 2007,^[2] the US Food and Drug Administration on October 31, 2008 ^[3] and Health Canada on February 9, 2012.^[4]

Fesoterodine is a prodrug. It is broken down into its active metabolite, 5-hydroxymethyl tolterodine, by plasma esterases.

Efficacy

Fesoterodine has the advantage of allowing more flexible dosage than other muscarinic antagonists.^[5] Its tolerability and side effects are similar to other muscarinic antagonists and as a new drug seems unlikely to make great changes in practices of treatment for overactive bladder.^[5]

References

^ "Fesoterodine, New Drug Candidate For Treatment For Overactive Bladder – Pfizer To Acquire Exclusive Worldwide Rights". Medical News Today. 17 April 2006.
^ "Toviaz: European Public Assessment Report, Revision 3 - Published 02/06/08". European Medicines Agency. 2 June 2008.
^ "Pfizer's Toviaz (fesoterodine fumarate) Receives FDA Approval for the Treatment of Overactive Bladder" (Press release). Pfizer Inc. 2008-10-31. Retrieved 2008-11-06.
^ Notice of Decision for TOVIAZ
^ ^a ^b Vella, M.; Cardozo, L. (2011). "Review of fesoterodine". Expert Opinion on Drug Safety 10 (5): 805–808. doi:10.1517/14740338.2011.591377. PMID 21639817.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 女性における尿失禁の治療 treatment of urinary incontinence in women
2. 男性における下部尿路症状 lower urinary tract symptoms in men
3. 前立腺肥大症の内科的治療 medical treatment of benign prostatic hyperplasia
4. 男性の尿失禁 urinary incontinence in men
5. 患者情報：女性に対する尿失禁の治療（詳細） urinary incontinence treatments for women beyond the basics

English Journal

Effect of fesoterodine on urethral closure function in women with stress urinary incontinence assessed by urethral pressure reflectometry.

Klarskov N1, Darekar A, Scholfield D, Whelan L, Lose G.
International urogynecology journal.Int Urogynecol J.2014 Jun;25(6):755-60. doi: 10.1007/s00192-013-2269-6. Epub 2013 Nov 21.
INTRODUCTION AND HYPOTHESIS: The aim was to evaluate, using urethral pressure reflectometry (UPR), the effect of fesoterodine on urethral function in women with stress urinary incontinence (SUI).METHODS: Women aged 18 to 65 years were eligible for this randomised, double-blind, placebo-controlled,
PMID 24258099

An observational study of patient satisfaction with fesoterodine in the treatment of overactive bladder: effects of additional educational material.

Schneider T1, Arumi D, Crook TJ, Sun F, Michel MC.
International journal of clinical practice.Int J Clin Pract.2014 May 5. doi: 10.1111/ijcp.12450. [Epub ahead of print]
AIM: To compare the effects of additional educational material on treatment satisfaction of overactive bladder (OAB) patients treated with a muscarinic receptor antagonist.METHODS: In an observational study of OAB patients being treated by their physician with fesoterodine for 4 months (FAKTEN stud
PMID 24797765

Cost effectiveness of fesoterodine and tolterodine for the treatment of overactive bladder with urge urinary incontinence in Spain and Finland.

Angulo JC1, Valpas A, Rejas J, Linden K, Kvasz M, Snedecor SJ.
Clinical drug investigation.Clin Drug Investig.2014 May;34(5):297-307. doi: 10.1007/s40261-014-0178-1.
BACKGROUND: Overactive bladder is a prevalent condition worldwide that is associated with a considerable burden, both on the patient and on society.OBJECTIVE: Our objective was to assess the economic value of fesoterodine compared with tolterodine extended release (ER) for the treatment of overactiv
PMID 24567280

Japanese Journal

フェソテロジンフマル酸塩（トビエース<sup>®</sup>錠4 mg・8 mg）の薬理学的特徴および臨床試験成績

日本薬理学雑誌 143(4), 203-213, 2014
NAID 130003391447

臨床新薬レビューフェソテロジンフマル酸塩 Fesoterodine Fumarate トビエース錠ファイザー株式会社

MD : medical doctor : 明日を創る医療総合誌 10(9), 34-36, 2013-09
NAID 40019794787

Related Pictures

★リンクテーブル★

リンク元

「フェソテロジン」

Fesoterodine
Systematic (IUPAC) name
	[2-[(1R)-3-(Di(propan-2-yl)amino)-1-phenylpropyl]-4-(hydroxymethyl)phenyl] 2-methylpropanoate
Clinical data
Trade names	Toviaz
AHFS/Drugs.com	monograph
MedlinePlus	a609021
Licence data	EMA:Link, US FDA:link
Pregnancy; category	US: C (Risk not ruled out); ;
Legal status	℞ (Prescription only);
Routes of; administration	Oral
Pharmacokinetic data
Bioavailability	52% (active metabolite)
Protein binding	50% (active metabolite)
Metabolism	Hepatic (CYP2D6- and 3A4-mediated)
Biological half-life	7–8 hours (active metabolite)
Excretion	Renal (70%) and fecal (7%)
Identifiers
CAS Registry Number	286930-03-8
ATC code	G04BD11
PubChem	CID: 6918558
IUPHAR/BPS	7473
DrugBank	DB06702
ChemSpider	5293755
UNII	621G617227
KEGG	D07226
ChEMBL	CHEMBL1201764
Chemical data
Formula	C26H37NO3
Molecular mass	411.278 g/mol
	SMILES O=C(Oc1ccc(cc1[C@@H](c2ccccc2)CCN(C(C)C)C(C)C)CO)C(C)C ;
	InChI InChI=1S/C26H37NO3/c1-18(2)26(29)30-25-13-12-21(17-28)16-24(25)23(22-10-8-7-9-11-22)14-15-27(19(3)4)20(5)6/h7-13,16,18-20,23,28H,14-15,17H2,1-6H3/t23-/m1/s1 ; Key:DCCSDBARQIPTGU-HSZRJFAPSA-N ;
(what is this?) (verify)

　　[★]

英: fesoterodine
商: トビエース

過活動膀胱治療剤

膀胱平滑筋に存在するムスカリン受容体に結合して膀胱収縮を抑制する。

フェソテロジン　→　5-HMT

[1] "Fesoterodine, New Drug Candidate For Treatment For Overactive Bladder – Pfizer To Acquire Exclusive Worldwide Rights". Medical News Today. 17 April 2006.

[2] "Toviaz: European Public Assessment Report, Revision 3 - Published 02/06/08". European Medicines Agency. 2 June 2008.

[3] "Pfizer's Toviaz (fesoterodine fumarate) Receives FDA Approval for the Treatment of Overactive Bladder" (Press release). Pfizer Inc. 2008-10-31. Retrieved 2008-11-06.

[4] Notice of Decision for TOVIAZ

[Vella2011-5] Vella, M.; Cardozo, L. (2011). "Review of fesoterodine". Expert Opinion on Drug Safety 10 (5): 805–808. doi:10.1517/14740338.2011.591377. PMID 21639817.

匿名

検索

案内

案内

fesoterodine